Dr. Spyro Mousses

Dr. Spyro Mousses is currently CEO at Systems Oncology.

Prior to this he was the Chief Scientist and Executive Scientific Advisor for the Sharon Disney Lund Medical Intelligence and Innovation Institute (MI3) at Children’s Hospital of Orange County (CHOC). Dr. Mousses received his BSc (1991) (Pharmacology and Toxicology), MSc (1993) and PhD (1998) (Molecular Pathogenesis and Genetics of Cancer), from the University of Toronto, Canada. He served as Staff Scientist at the National Human Genome Research Institute, National Institutes of Health where he led a program in cancer genome scanning and high throughput technology development (1998-2002). After serving at the NIH, he joined theTranslational Genomics Research Institute (TGen) at the inception of the Institute as one of the founding scientists (2002-2013).

Most recently, he served as Vice President for Innovation at TGen, where he developed and managed industry partnerships to co-develop innovative molecular medicine solutions and initiatives with industry. He also served as TGen’s Director of the Pharmaceutical Genomics Division (8 laboratories, staff of 50), where he led the development of more than 30 programs and directly collaborated with multiple pharmaceutical industry sponsors (including Lilly, GSK, Novartis, SanofiAventis, BMS, AstraZeneca) to drive research programs and conduct pharmacogenomics studies in support of drug discovery and development. As an entrepreneur in residence at TGen, he founded multiple biotech and IT companies including; Systems Medicine Inc., a biotech company acquired by Cell Therapeutics Inc. in Seattle WA; MedTrust Online Inc., acquired by Annai Systems Inc. Los Gatos, CA. As Director of TGen’s Center for BioIntelligence, his team invented the BioIntelligence Framework, a game changing knowledge-computing platform.

At the end of 2013, the BioIntelligence vision was mature enough to be industrialized, so TGen’s Center for BioIntelligence was spun-off. On January 2014, Systems Imagination Inc. (SII) was formed to commercialize that vision, and the SII team spun out of TGen to begin offering industrial scale services to enterprises and collaborative groups. Currently, Dr. Mousses serves on the board of SII, and serves as an executive advisor for multiple companies ranging from start-ups to large pharmaceutical companies. As an executive scientific advisor and entrepreneur in residence at CHOC, Dr. Mousses is also focused on creating a culture of innovation at CHOC, to enable both CHOC and the international pediatrics community to accelerate the process of driving innovations from mind to market.